A detailed history of Pathstone Holdings, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Pathstone Holdings, LLC holds 6,847 shares of NBIX stock, worth $927,220. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,847
Previous 9,543 28.25%
Holding current value
$927,220
Previous $1.31 Million 39.98%
% of portfolio
0.0%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$114.58 - $153.15 $308,907 - $412,892
-2,696 Reduced 28.25%
6,847 $788,000
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $550,397 - $602,257
4,206 Added 78.81%
9,543 $1.31 Million
Q1 2024

May 13, 2024

SELL
$130.4 - $143.74 $134,442 - $148,195
-1,031 Reduced 16.19%
5,337 $736,000
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $675,453 - $845,415
6,368 New
6,368 $839,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Pathstone Holdings, LLC Portfolio

Follow Pathstone Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Holdings, LLC with notifications on news.